Abstract 351P
Background
Waldenstrom macroglobulinemia (WM) is a very rare disease. It also known as lymphoplasmacytic lymphoma, a low grade-B cell lymphoproliferative neoplasm characterized by monoclonal IgM gammopathy. The diagnosis of WM is challenging and data regarding clinical features and treatment outcomes in Indonesia is limited. The aim of this study is to investigate clinical features, treatments and outcomes of WM patients in the tertiary referral cancer center in Jakarta, Indonesia.
Methods
This was a retrospective cohort study conducted in outpatient oncology clinic in a tertiary referral cancer center in Jakarta, Indonesia from 2022 until 2023. It included all patients with working diagnosis WM based on Waldenstrom Macroglobulinemia International Workshop Criteria. Demographic data, clinical features, treatments, and outcomes were collected.
Results
We evaluated a total of 8 patients. Most of the patients (62.5%) were male, with mean age 61.1 + 8.6 years old. All patients had symptoms of anemia such weakness, light-headedness, and shortness of breath. Median hemoglobin was 8.46 (6.0 – 13.1) g/dL. Mean immunoglobulin (Ig)M was 3832. Three (37.5%) patients had autoimmune hemolytic anemia (AIHA), and 3 (37.5%) patients had organomegaly. Seventy percent patients received systemic therapy, mostly (66.7%) with Cyclophosphamide Vincristine Prednisone (CVP) regiment. Among those who had systemic therapy, two (33.3%) patients died, and 1 (16.6%) patient transformed into acute myeloid leukemia (AML).
Conclusions
The clinical features of WM were male sex, elderly, anemia, had AIHA, high IgM and organomegaly. Most patients underwent systemic therapy but had unfavorable responses. Further studies should focus on predictors of survival on WM patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract